Post-earnings recap
Reported
Tue, Nov 7, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Celldex Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising 10.08%. The company did not provide revenue figures or future guidance, but management's comments on clinical progress may have reassured investors. The stock's increase reflects investor confidence in the company's ongoing projects despite the lack of detailed financial guidance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.20 | N/A | +14.93% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a sense of cautious optimism regarding their ongoing projects. They acknowledged the hurdles but emphasized their commitment to advancing their therapies.
Management highlighted progress in their clinical trials.
They expressed confidence in their pipeline but noted the challenges ahead.